We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+12.05%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.07B
AUM Growth
-$249M
Cap. Flow
-$414M
Cap. Flow %
-13.47%
Top 10 Hldgs %
34.44%
Holding
117
New
6
Increased
34
Reduced
30
Closed
8

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$18.4M
2
ZBIO
Zenas BioPharma
ZBIO
+$15.8M
3
SMMT icon
Summit Therapeutics
SMMT
+$14.5M
4
NUVL
Nuvalent
NUVL
+$14.4M
5
CYTK icon
Cytokinetics
CYTK
+$11.5M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$168M
2
IDXX icon
Idexx Laboratories
IDXX
+$58.2M
3
EVH icon
Evolent Health
EVH
+$51.7M
4
BSX icon
Boston Scientific
BSX
+$28.2M
5
ACHC icon
Acadia Healthcare
ACHC
+$26.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.71%
2 Consumer Staples 1.99%
3 Financials 0.11%
4 Industrials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
76
DELISTED
SpringWorks Therapeutics
SWTX
$6.4M 0.21%
199,855
– –
BHVN icon
77
Biohaven
BHVN
$2.1B
$6.37M 0.21%
127,558
– –
BEAM icon
78
Beam Therapeutics
BEAM
$2.78B
$6.12M 0.2%
249,923
– –
PCRX icon
79
Pacira BioSciences
PCRX
$969M
$6.02M 0.2%
400,000
-385,000
-49% -$6.58M
NAMS icon
80
NewAmsterdam Pharma
NAMS
$3.36B
$5.87M 0.19%
+353,319
New +$6.11M
MRSN
81
DELISTED
Mersana Therapeutics
MRSN
$5.76M 0.19%
121,871
– –
LUNG icon
82
Pulmonx
LUNG
$101M
$5.73M 0.19%
691,300
+38,900
+6% +$281K
ABOS icon
83
Acumen Pharmaceuticals
ABOS
$178M
$5.7M 0.19%
2,300,059
– –
CATX icon
84
Perspective Therapeutics
CATX
$355M
$5.53M 0.18%
414,396
+13,200
+3% +$176K
PLRX icon
85
Pliant Therapeutics
PLRX
$65.6M
$4.32M 0.14%
384,996
– –
EPIX
86
DELISTED
ESSA Pharma
EPIX
$4.1M 0.13%
677,005
– –
FOCL
87
EDAP TMS S.A.
FOCL
$231M
$4M 0.13%
1,568,000
+93,000
+6% +$381K
AUTL
88
Autolus Therapeutics
AUTL
$625M
$3.75M 0.12%
1,032,988
– –
MGNX icon
89
MacroGenics
MGNX
$259M
$3.47M 0.11%
1,053,647
– –
CYPH
90
Cypherpunk Technologies Inc
CYPH
$73.1M
$3.26M 0.11%
1,266,546
– –
GOSS icon
91
Gossamer Bio
GOSS
$86.1M
$3.22M 0.1%
3,266,960
– –
ACRS icon
92
Aclaris Therapeutics
ACRS
$864M
$3.17M 0.1%
2,753,495
– –
XLO icon
93
Xilio Therapeutics
XLO
$60.4M
$2.37M 0.08%
214,519
– –
APLS
94
DELISTED
Apellis Pharmaceuticals
APLS
$2.31M 0.08%
80,000
-60,700
-43% -$2.25M
ADAP
95
DELISTED
Adaptimmune Therapeutics
ADAP
$2.31M 0.08%
2,425,468
– –
SGMT icon
96
Sagimet Biosciences
SGMT
$600M
$2.18M 0.07%
787,808
– –
BMEA icon
97
Biomea Fusion
BMEA
$94.2M
$1.83M 0.06%
181,147
– –
CGEN icon
98
Compugen
CGEN
$232M
$1.79M 0.06%
989,990
– –
VIGL
99
DELISTED
Vigil Neuroscience
VIGL
$1.6M 0.05%
471,958
– –
SPRB
100
Spruce Biosciences
SPRB
$128M
$1.24M 0.04%
34,788
– –
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Rock Springs Capital Management held 117 positions worth $3.07B, down 7.5% from $3.32B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management withdrew a net $414M in Q3 2024, closing 8 positions and reducing 30 holdings. Its most notable exit was Idexx Laboratories, an estimated $58.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Zenas BioPharma worth $14.9M.

  • Rock Springs Capital Management's largest Q3 2024 buy was Zenas BioPharma: 878,667 shares worth $14.9M.
  • Rock Springs Capital Management added most to Eli Lilly in Q3 2024, an estimated $18.4M increase.
  • Rock Springs Capital Management's biggest Q3 2024 reduction was Blueprint Medicines, cutting an estimated $168M.
  • Rock Springs Capital Management fully exited Idexx Laboratories in Q3 2024, selling an estimated $58.2M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $3.07B portfolio in Q3 2024.
  • Rock Springs Capital Management opened 6 new positions and closed 8 in Q3 2024.
  • Rock Springs Capital Management's portfolio value fell 7.5% quarter-over-quarter to $3.07B.

Based on Rock Springs Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.